Day One Biopharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by. Once again, I'd like to turn the floor over to Joey Peroni, Senior Vice President of Finance and Investor Relations. Please begin.

Thank you. Hello, everyone, and good afternoon. Welcome to day one's first quarter financial and operating results conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release and the slides to accompany this conference call on the Investors and Media section of our website at www.dayonebio.com. An audio webcast with the corresponding slides is also available on the website. Before we get started, I'd like to remind everyone that some of the statements that we make on this call and the information presented in the slide deck include forward-looking statements as outlined on slide two. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. We encourage you to review the various risks, uncertainties, and other factors included in our most recent filings with the SEC and any other future filings that we may make with the SEC. These forward-looking statements are based on our current estimates and various assumptions and reflect management's intentions, beliefs, and expectations about future events, strategies, competition, products, and product candidates, operating plans, and performance. Your caution not to place any undue reliance on these forward-looking statements and accept as required by law day one disclaims any obligation to update such statements. Today, I'm joined by Dr. Jeremy Bender, Chief Executive Officer, Laura Maradino, Chief Commercial Officer, Charles York, Chief Operating and Financial Officer, and Ellie Berry, Chief Medical Officer. I will now turn the call over to Jeremy.

Thank you, Joey, and good afternoon. I'm excited to share that we achieved another quarter of growth and strong financial performance to start the year. I'm thrilled by the progress we have made thus far in bringing Ojemda to patients in need. We continue to execute on the three priorities we laid out for our business in 2025 earlier this year. The first is establishing Ojemda as the standard of care in second-line plus pediatric low-grade glioma and driving Ojemda revenue growth. The second is advancing our clinical development pipeline for Firefly 2 and Day 301. And the third is further expanding our portfolio. In the first quarter of 2025, Ojemda quarterly scripts increased to over 900, representing 16% growth over total scripts in the prior quarter. This growth drove net product revenue for Ojemda to $30.5 million for Q1 2025. Our consistent growth each quarter since launch and the market dynamics we've observed over the past 12 months have further reinforced that Ojemda is a foundational opportunity for day one that will drive durable, long-term value creation. Significant untapped potential remains for Ojemda in relapsed refractory PLGG. Prescriber adoption continues to increase, on-label patient demand has grown steadily, payer approval rates are high, and patients continue to experience longer treatment periods on Ojemda as time progresses. All of these data points give us confidence that the steady increase in Ojemda revenue will continue. Beyond Ojemda's commercial performance, we remain focused on building value across our pipeline. We are encouraged by the enrollment progress we've observed in our global Firefly 2 confirmatory trial. We expect the trial will be fully enrolled in the first half of 2026 as we endeavor to drive expansion of Ojemda beyond the relapsed refractory PLGG approval and into the frontline PLGG setting. Additionally, our partner, Hipson, recently announced that their application for tovorafenib was accepted by the EMA for review, bringing it one step closer to patients in that region who remain in need of a new treatment option. Our Day 301 program also continues to advance through the dose escalation portion of the Phase 1A trial. Our successful track record with Ojemda has paved the way for us to continue to discover and develop first-in-class or best-in-class programs for both children and adults. We remain committed to and are actively evaluating business development opportunities that will allow us to expand our multi-program clinical stage portfolio aimed at driving sustained long-term growth. This is an exciting moment for day one. 2025 is off to a great start. We have a solid financial foundation that provides us with multiple options for value creation in the coming quarters, even during a period when macroeconomic factors present existential challenges and uncertainties for many biotech companies. Ojemda's launch continues to deliver solid growth, and I am proud of the progress we have established with a clear path for long-term financial and program success for the company. I'll now turn the call over to Lauren to discuss our commercial progress in greater detail.